Drug, Biotech Firms Push Regulatory Reform

Regulatory Reform Author: Kathryn S. Brown Listening to the radio on his way to work each morning in Washington D.C., Stephen Bent, chairman of the biotechnology and pharmaceutical group at the law firm of Foley and Lardner, hears the same thing: advertisements calling for drastic reform of the Food and Drug Administration (FDA). "Some of the commercials are by a Republican think tank," notes Bent, formerly a research scientist in neurophysiology at Yale University. "Some are by various inter

Kathryn Brown
Jan 21, 1996

Regulatory Reform Author: Kathryn S. Brown

Listening to the radio on his way to work each morning in Washington D.C., Stephen Bent, chairman of the biotechnology and pharmaceutical group at the law firm of Foley and Lardner, hears the same thing: advertisements calling for drastic reform of the Food and Drug Administration (FDA).

"Some of the commercials are by a Republican think tank," notes Bent, formerly a research scientist in neurophysiology at Yale University. "Some are by various interest groups. And some, I just don't know who they're by."

But Bent says he does know one thing: "Phar- maceutical corporations are on a bandwagon whose time has come." In an era of pro-streamlining, anti-regulatory, pro-corporate sentiment, Bent predicts, pharmaceutical and biotech companies stand to win or gain ground in many regulatory battles with various government agencies.

The new year offers plenty of issues. As 1996 begins, companies are poised to...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?